Aminoglycoside resistance rates, phenotypes, and mechanisms of gram-negative bacteria from infected patients in upper Egypt

PLoS ONE

Volumn 6, Issue 2, 2011, Pages

  Gad, Gamal F ^a   Mohamed, Heba A ^a   Ashour, Hossam M ^b,c  

^a Minia University   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

^c WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; BETA LACTAM; CIPROFLOXACIN; GENTAMICIN; KANAMYCIN; NEOMYCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STREPTOMYCIN; TOBRAMYCIN; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CITROBACTER KOSERI; EAR INFECTION; EFFUSION; EGYPT; ENTEROBACTER AEROGENES; ENZYME ASSAY; ESCHERICHIA COLI; GASTROINTESTINAL INFECTION; HUMAN; KLEBSIELLA PNEUMONIAE; MICROBIAL ACTIVITY; MINIMUM INHIBITORY CONCENTRATION; MORGANELLA MORGANII; NONHUMAN; PHENOTYPIC VARIATION; PROTEUS VULGARIS; PSEUDOMONAS AERUGINOSA; SERRATIA MARCESCENS; SKIN INFECTION; URINARY TRACT INFECTION; BACTERIAL SKIN DISEASE; DRUG EFFECT; EAR DISEASE; GASTROINTESTINAL DISEASE; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; ISOLATION AND PURIFICATION; MICROBIOLOGY; PHENOTYPE; PHYSIOLOGY;

ESCHERICHIA COLI; NEGIBACTERIA; PSEUDOMONAS AERUGINOSA;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; EAR DISEASES; EGYPT; GASTROINTESTINAL DISEASES; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; PHENOTYPE; SKIN DISEASES, BACTERIAL; URINARY TRACT INFECTIONS;

EID: 79951934857     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0017224     Document Type: Article

References (36)

1. Hermann T, (2007) Aminoglycoside antibiotics: old drugs and new therapeutic approaches. Cell Mol Life Sci 64: 1841-1852.
2. Shakil S, Khan R, Zarrilli R, Khan AU, (2008) Aminoglycosides versus bacteria-a description of the action, resistance mechanism, and nosocomial battleground. J Biomed Sci 15: 5-14.
3. Mingeot-Leclercq MP, Glupczynski Y, Tulkens PM, (1999) Aminoglycosides: activity and resistance. Antimicrob Agents Chemother 43: 727-737.
4. Falagas ME, Grammatikos AP, Michalopoulos A, (2008) Potential of old-generation antibiotics to address current need for new antibiotics. Expert Rev Anti Infect Ther 6: 593-600.
5. Davies J, Wright GD, (1997) Bacterial resistance to aminoglycoside antibiotics. Trends Microbiol 5: 234-240.
6. Shaw KJ, Rather PN, Hare RS, Miller GH, (1993) Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes. Microbiol Rev 57: 138-163.
7. Llano-Sotelo B, Azucena EF Jr, Kotra LP, Mobashery S, Chow CS, (2002) Aminoglycosides modified by resistance enzymes display diminished binding to the bacterial ribosomal aminoacyl-tRNA site. Chem Biol 9: 455-463.
8. Sobel ML, McKay GA, Poole K, (2003) Contribution of the MexXY multidrug transporter to aminoglycoside resistance in Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 47: 3202-3207.
9. Vogne C, Aires JR, Bailly C, Hocquet D, Plesiat P, (2004) Role of the multidrug efflux system MexXY in the emergence of moderate resistance to aminoglycosides among Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 48: 1676-1680.
10. Hocquet D, Vogne C, El Garch F, Vejux A, Gotoh N, et al. (2003) MexXY-OprM efflux pump is necessary for a adaptive resistance of Pseudomonas aeruginosa to aminoglycosides. Antimicrob Agents Chemother 47: 1371-1375.
11. Vakulenko SB, Mobashery S, (2003) Versatility of aminoglycosides and prospects for their future. Clin Microbiol Rev 16: 430-450.
12. Gad GF, El-Domany RA, Zaki S, Ashour HM, (2007) Characterization of Pseudomonas aeruginosa isolated from clinical and environmental samples in Minia, Egypt: prevalence, antibiogram and resistance mechanisms. J Antimicrob Chemother 60: 1010-1017.
13. Abd-El-Haleem D, Kheiralla ZH, Zaki S, Rushdy AA, Abd-El-Rahiem W, (2003) Multiplex-PCR and PCR-RFLP assays to monitor water quality against pathogenic bacteria. J Environ Monit 5: 865-870.
14. Gad GF, el-Domany RA, Ashour HM, (2008) Antimicrobial susceptibility profile of Pseudomonas aeruginosa isolates in Egypt. J Urol 180: 176-181.
15. CLSI (2007) Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing; Fifteenth Informational Supplement CLSI document M100-S15, Clinical and Laboratory Standards Institute. Wayne, PA.
16. Livermore DM, Winstanley TG, Shannon KP, (2001) Interpretative reading: recognizing the unusual and inferring resistance mechanisms from resistance phenotypes. J Antimicrob Chemother 48 (Suppl 1): 87-102.
17. Benveniste R, Davies J, (1971) R-factor mediated gentamicin resistance: A new enzyme which modifies aminoglycoside antibiotics. FEBS Lett 14: 293-296.
18. Lomovskaya O, Warren MS, Lee A, Galazzo J, Fronko R, et al. (2001) Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob Agents Chemother 45: 105-116.
19. Lorian V, (2005) Antibiotics in laboratory medicine. Philadelphia Lippincott Williams & Wilkins pp. xiii, 889 p.
20. Cirioni O, Giacometti A, Kamysz W, Silvestri C, Riva A, et al. (2007) In vitro activities of tachyplesin III against Pseudomonas aeruginosa. Peptides 28: 747-751.
21. Drusano GL, Ambrose PG, Bhavnani SM, Bertino JS, Nafziger AN, et al. (2007) Back to the future: using aminoglycosides again and how to dose them optimally. Clin Infect Dis 45: 753-760.
22. Beauchamp D, Labrecque G, (2007) Chronobiology and chronotoxicology of antibiotics and aminoglycosides. Adv Drug Deliv Rev 59: 896-903.
23. Falagas ME, Kopterides P, (2007) Old antibiotics for infections in critically ill patients. Curr Opin Crit Care 13: 592-597.
24. Tsai TY, Chang SC, Hsueh PR, Feng NH, Wang JT, (2007) In vitro activity of isepamicin and other aminoglycosides against clinical isolates of Gram-negative bacteria causing nosocomial bloodstream infections. J Microbiol Immunol Infect 40: 481-486.
25. Kotra LP, Haddad J, Mobashery S, (2000) Aminoglycosides: perspectives on mechanisms of action and resistance and strategies to counter resistance. Antimicrob Agents Chemother 44: 3249-3256.
26. Schmitz FJ, Verhoef J, Fluit AC, (1999) Prevalence of aminoglycoside resistance in 20 European university hospitals participating in the European SENTRY Antimicrobial Surveillance Programme. Eur J Clin Microbiol Infect Dis 18: 414-421.
27. Over U, Gur D, Unal S, Miller GH, (2001) The changing nature of aminoglycoside resistance mechanisms and prevalence of newly recognized resistance mechanisms in Turkey. Clin Microbiol Infect 7: 470-478.
28. Shahid M, Malik A, (2005) Resistance due to aminoglycoside modifying enzymes in Pseudomonas aeruginosa isolates from burns patients. Indian J Med Res 122: 324-329.
29. Neonakis I, Gikas A, Scoulica E, Manios A, Georgiladakis A, et al. (2003) Evolution of aminoglycoside resistance phenotypes of four Gram-negative bacteria: an 8-year survey in a University Hospital in Greece. Int J Antimicrob Agents 22: 526-531.
30. Poole K, (2005) Aminoglycoside resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 49: 479-487.
31. Giamarellou H, (1986) Aminoglycosides plus beta-lactams against gram-negative organisms. Evaluation of in vitro synergy and chemical interactions. Am J Med 80: 126-137.
32. Fosse T, Soussy CJ, Duval J, (1983) [In vitro study of combinations between third-generation cephalosporins and aminoglycosides on Enterobacteriaceae]. Pathol Biol (Paris) 31: 483-487.
33. Goldin AB, Sawin RS, Garrison MM, Zerr DM, Christakis DA, (2007) Aminoglycoside-based triple-antibiotic therapy versus monotherapy for children with ruptured appendicitis. Pediatrics 119: 905-911.
34. Freundlich M, Thomsen RW, Pedersen L, West H, Schonheyder HC, (2007) Aminoglycoside treatment and mortality after bacteraemia in patients given appropriate empirical therapy: a Danish hospital-based cohort study. J Antimicrob Chemother 60: 1115-1123.
35. Leibovici L, Paul M, (2007) Aminoglycoside/beta-lactam combinations in clinical practice. J Antimicrob Chemother 60: 911-912.
36. Paul M, Silbiger I, Grozinsky S, Soares-Weiser K, Leibovici L, (2006) Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev: CD003344.